Metagenomi Therapeutics
77 hedge funds and large institutions have $38.8M invested in Metagenomi Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 13 reducing their positions, and 13 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
53% more capital invested
Capital invested by funds: $25.3M → $38.8M (+$13.5M)
15% more funds holding
Funds holding: 67 → 77 (+10)
2.45% less ownership
Funds ownership: 31.16% → 28.71% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.16M |
| 3 |
Morgan Stanley
New York
|
+$1.72M |
| 4 |
State Street
Boston,
Massachusetts
|
+$963K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$602K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.91M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.83M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.29M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.58M |
| 5 |
Millennium Management
New York
|
-$973K |
MGX Hedge Fund Activity: Q4 2024 in Review
77 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q4 2024, worth a combined $38.8M — up 53% from $25.3M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MGX positions and 13 closed out — a net gain of 10 holders — while 30 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $2.44M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $3.91M sold.
- 77 institutional investors held Metagenomi Therapeutics (MGX) as of Q4 2024, up from 67 in Q3 2024.
- Funds reported $38.8M of Metagenomi Therapeutics stock for Q4 2024, up 53% quarter-over-quarter.
- 23 funds opened new Metagenomi Therapeutics positions in Q4 2024 and 13 closed out, a net change of +10 holders.
- The largest Metagenomi Therapeutics buyer in Q4 2024 was BlackRock, an estimated $2.44M added.
- The largest Metagenomi Therapeutics seller in Q4 2024 was Novo Holdings A/S, an estimated $3.91M sold.
Based on aggregated 13F filings for Q4 2024.